期刊文献+

TRF2小干扰RNA载体的构建及表达 被引量:2

Construction and expression of telomeric repeat binding factor 2 small interfering RNA eukaryotic vector
下载PDF
导出
摘要 目的:构建TRF2小干扰RNA载体,观察其在胃癌细胞中的表达.方法:根据pSilencer3.1-H1载体要求设计两对小干扰RNA,退火后连接入载体相应位点.经双酶切及测序鉴定后分别转染多药耐药衍生胃癌细胞SGC7901/ADR和SGC7901/VCR. G418选择培养液培养2 mo选取转染组及对照组细胞克隆.MTT法检测转染对细胞生长增殖速度的影响.细胞用阿霉素和足叶乙甙处理 6h后Western blot法检测TRF2表达.结果:成功构建TRF2小干扰RNA载体,建立稳定转染细胞株,转染后TRF2表达明显降低,对细胞的生长增殖速度无明显影响(P>0.05).结论:成功构建TRF2小干扰RNA载体及稳定转染细胞株. AIM: To construct telomeric repeat binding factor 2 (TRF2) small interfering RNA (siRNA) eukaryotic expression vector and evaluate its expression in gastric cancer cells. METHODS: Two pairs of hairpin siRNA template oligonucleotides for TRF2 based on pSilencer3.1-H1 vector were designed using the manufacturer's web-based tool. These oligonucleotides were annealed and ligated into vector respectively. After confirmation by double enzyme digestion analysis and DNA sequencing, positive recombinant plasmids were transfected into multidrug-resistant gastric cancer cells SGC7901/ADR and SGC7901/VCR respectively. Stable cell lines of G418-resistance were acquired after 2-month selection. The effect of transfection on cell growth was analyzed by MTT assay. The expression of TRF2 was detected by Western blot after the cells treated with adriamycin (ADR) or etoposide for 6 h. RESULTS: We constructed two TRF2 siRNA eukaryotic expression vectors successfully and the transfected cells showed significantly suppressed TRF2 expression. The growth of cells were not significantly influenced by transfection (P 〉 0.05). CONCLUSION: The TRF2 siRNA eukaryotic expression vectors are successfully constructed and stably expressed in gastric cancer cells.
出处 《世界华人消化杂志》 CAS 北大核心 2006年第11期1044-1047,共4页 World Chinese Journal of Digestology
基金 国家自然科学基金资助项目 No.30400016
关键词 端粒重复序列结合因子2 胃癌 小干扰RNA Telomeric repeat binding factor 2 Gas-tric carcinoma Small interfering RNA
  • 相关文献

参考文献26

  • 1Houghtaling BR, Cuttonaro L, Chang W, Smith S. A dynamic molecular link between the telomere length regulator TRF1 and the chromosome end protector TRF2. Curr Biol 2004; 14: 1621-1631
  • 2Wright WE, Shay JW. Telomere-binding factors and general DNA repair. Nat Genet 2005; 37: 116-118
  • 3Gatti L, Zunino F. Overview of tumor cell chemore-sistance mechanisms. Methods Mol Med 2005; 111: 127-148
  • 4Tserng KY, Ingalls ST, Boczko EM, Spiro TP, Li X, Majka S, Gerson SL, Willson JK, Hoppel CL. Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine. J Clin Pharmacol 2003; 43: 881-893
  • 5Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279
  • 6Liu L, Gerson SL. Therapeutic impact of methoxya-mine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 2004; 5: 623-627
  • 7Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005; 31: 603-617
  • 8Liu D, O'Connor MS, Qin J, Songyang Z. Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins. J Biol Chem 2004; 279: 51338-51342
  • 9de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19: 2100-2110
  • 10Ye JZ, Hockemeyer D, Krutchinsky AN, Loayza D, Hooper SM, Chait BT, de Lange T. POT1-interacting protein PIP1: a telomere length regulator that rec-ruits POT1 to the TIN2/TRF1 complex. Genes Dev 2004; 18: 1649-1654

同被引文献32

  • 1韩德五.肝功能衰竭发病机制的研究─—肠源性内毒素血症假说[J].肝脏病杂志,1995,3(3):134-137. 被引量:111
  • 2高利利,吴本俨,王孟薇,黄海力,伍银桥,尤纬缔,王卫华.胃癌相关基因GCRG213正反义真核表达载体的构建及鉴定[J].世界华人消化杂志,2006,14(15):1453-1457. 被引量:4
  • 3靳西凤,冉志华.RNA干扰技术与结肠癌[J].世界华人消化杂志,2006,14(20):2003-2008. 被引量:4
  • 4刘明社,王兰,赵中夫,张国英,张芸,封江南.干扰Fas受体表达的串联shRNA表达载体的构建[J].世界华人消化杂志,2006,14(22):2174-2179. 被引量:6
  • 5李巍,田素礼,李季.癌基因C-erbB-2在结直肠癌中的表达及其与浸润转移的相关性[J].世界华人消化杂志,2006,14(33):3206-3211. 被引量:1
  • 6Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296:550-553.
  • 7Belladonna ML, Vacca C, Volpi C, Giampietri A, Fioretti MC, Puccetti P, Grohmann U, Campanile F. IL-23 neutralization protects mice from Gramnegative endotoxic shock. Cytokine 2006; 34:161-169.
  • 8Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, CappareIli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999; 13:1015-1024.
  • 9Loniewski KJ, Patial S, Parameswaran N. Sensitivity of TLR4- and -7-induced NF kappa B1 p105-TPL2- ERK pathway to TNF-receptor-associated-factor-6 revealed by RNAi in mouse macrophages. Mol Immunol 2007; 44:3715-3723.
  • 10Yang YJ, Chen W, Carrigan SO, Chen WM, Roth K, Akiyama T, Inoue J, Marshall JS, Berman JN, Lin TJ. TRAF6 specifically contributes to FcepsilonRImediated cytokine production but not mast cell degranulation. J Biol Chem 2008; 283:32110-32118.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部